INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA Registrationfilings in Bladder,
View HTML
Toggle Summary San Diego key part of program to beat cancer by 2020
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowess By Bradley J. Fikes (/staff/bradley-fikes/) | 3:33 p.m. March 3, 2016 If physician turned billionaire biotech entrepreneur Dr. Patrick Soon-Shiong succeeds in his ambitious goal to defeat cancer by 2020, San Diego County's
View HTML
Toggle Summary Sorrento and Conkwest Announce Exclusive Global Collaboration Developing Next Generation Cancer Immunotherapy with “Off-the-Shelf” Chimeric Antigen Receptor–Tumor Attacking Natural Killer (CAR-taNK™) Cell Lines
San Diego and Cardiff-by-the-Sea, CA (Dec. 19, 2014) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ® , a Natural
View HTML